Sunitinib Accord Unión Europea - neerlandés - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische middelen - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Jayempi Unión Europea - neerlandés - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graft rejection - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Fingolimod Mylan Unión Europea - neerlandés - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multiple sclerose, relapsing-remitting - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 en 5. 1)orpatients met zich snel ontwikkelende ernstige relapsing-remitting multiple sclerose gedefinieerd door 2 of meer het uitschakelen van de recidieven in één jaar, en met 1 of meer gadolinium aankleurende laesies op de mri van de hersenen of een significante toename in t2-laesies belasting in vergelijking met een eerdere recente mri.

Humira Unión Europea - neerlandés - EMA (European Medicines Agency)

humira

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosuppressiva - raadpleeg het document met productinformatie.

Efavirenz/Emtricitabine/Tenofovirdisoproxil Sandoz 600 mg/200 mg/245 mg, filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

efavirenz/emtricitabine/tenofovirdisoproxil sandoz 600 mg/200 mg/245 mg, filmomhulde tabletten

sandoz b.v. veluwezoom 22 1327 ah almere - efavirenz ; emtricitabine ; tenofovirdisoproxilsuccinaat samenstelling overeenkomend met ; tenofovirdisoproxil - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; poloxameer 407 ; polyvinylalcohol (e1203) ; talk (e 553 b) ; titaandioxide (e 171), - emtricitabine, tenofovir disoproxil and efavirenz

Padviram 600 mg/200 mg/245 mg, filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

padviram 600 mg/200 mg/245 mg, filmomhulde tabletten

sandoz b.v. veluwezoom 22 1327 ah almere - efavirenz ; emtricitabine ; tenofovirdisoproxilsuccinaat samenstelling overeenkomend met ; tenofovirdisoproxil - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; poloxameer 407 ; polyvinylalcohol (e1203) ; talk (e 553 b) ; titaandioxide (e 171), - emtricitabine, tenofovir disoproxil and efavirenz

Zolestad 5 mg/100 ml, oplossing voor infusie Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zolestad 5 mg/100 ml, oplossing voor infusie

stada arzneimittel ag stadastrasse 2-18 61118 bad vilbel (duitsland) - zoledroninezuur 1-water samenstelling overeenkomend met ; zoledroninezuur 0-water - oplossing voor infusie - mannitol (d-) (e 421) ; stikstof (head space) (e 941) ; trinatriumcitraat 2-water (e 331) ; water voor injectie, - zoledronic acid

Abacavir Hexal 300 mg, filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abacavir hexal 300 mg, filmomhulde tabletten

hexal ag industriestrasse 25 d-83607 holzkirchen (duitsland) - abacavir 300 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; ijzeroxide geel (e 172) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polyethyleenglycol (e 1521) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; ijzeroxide geel (e 172) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polyethyleenglycol (e 1521) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - abacavir

Abacavir/Lamivudine DOC Generici, 600 mg/300 mg filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abacavir/lamivudine doc generici, 600 mg/300 mg filmomhulde tabletten

doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - abacavir ; lamivudine 0-water - filmomhulde tablet - cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 90 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; povidon k 90 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), - lamivudine and abacavir

Abacavir/Lamivudine PharOS, 600 mg/300 mg filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abacavir/lamivudine pharos, 600 mg/300 mg filmomhulde tabletten

pharos pharmaceutical oriented services ltd - abacavir ; lamivudine 0-water - filmomhulde tablet - cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 90 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; povidon k 90 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), - lamivudine and abacavir